Aradigm Receives FDA Orphan Drug Designation
Posted on: Tuesday, 16 January 2007, 12:01 CST
Aradigm Corporation has received orphan drug designation from the FDA for an inhaled liposomal formulation of ciprofloxacin for the management of bronchiectasis.
Aradigm previously received orphan drug designation for the same formulation of ciprofloxacin for the management of cystic fibrosis in April 2006.
Aradigm's liposomal ciprofloxacin is an aerosolized formulation that was designed to prolong its anti-infective properties in the lung in order to treat the related infections found in bronchiectasis (BE) and cystic fibrosis, while minimizing the concentration of the drug in the rest of the body.
"We are very pleased with the orphan drug designation for an additional indication for our inhaled liposomal ciprofloxacin formulation. The orphan drug designation continues to support our strategy to help patients with severe respiratory disease," said Babatunde Otulana, senior vice president of Development at Aradigm.
Orphan drug designation is given to therapies for diseases that affect fewer than 200,000 patients. As an orphan drug, liposomal ciprofloxacin is eligible for tax credits, as well as assistance from the FDA. The designation also provides the opportunity to obtain market exclusivity for seven years.
Source: Datamonitor
Related Articles
- Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
- Celator Receives Orphan Drug Designation for Leukemia Drug
- Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
- Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
- Lilly Lymphoma Drug Designated Orphan Status
- Alfacell Drug Designated Orphan Product
- Agennix Receives Orphan Drug Designation for Cancer Treatment
- Agennix Receives FDA Orphan Drug Designation for Talactoferrin Alfa in Renal Cell Carcinoma
- Xechem Receives Orphan Drug Designation From The FDA For Its Anti-Sickling Drug 5-HMF
- Aradigm Receives FDA Orphan Drug Designation of Liposomal Ciprofloxacin for Cystic Fibrosis
 |
 |
User Comments (0)
RSS Feeds